TNFAIP3 Antibody

Size

100ug

Clone Number

Aliases

A20 antibody; AISBL antibody; MGC104522 antibody; MGC138687 antibody; MGC138688 antibody; OTU domain containing protein 7C antibody; OTU domain-containing protein 7C antibody; OTUD7C antibody; Putative DNA binding protein A20 antibody; Putative DNA-binding protein A20 antibody; TNAP3_HUMAN antibody; TNF alpha-induced protein 3 antibody; TNFA1P2 antibody; TNFAIP 3 antibody; TNFAIP3 (A20) antibody; TNFAIP3 antibody; Tumor necrosis factor alpha induced protein 3 antibody; Tumor necrosis factor alpha-induced protein 3 antibody; Tumor necrosis factor induced protein 3 antibody; Tumor necrosis factor inducible protein A20 antibody; tumor necrosis factor, alpha-induced protein 3 antibody; Zinc finger protein A20 antibody

Immunogen Species

Homo sapiens (Human)

UniProt ID

P21580

Immunogen

Recombinant Human Tumor necrosis factor alpha-induced protein 3 protein (97-183AA)

Raised in

Rabbit

Species Reactivity

Human, Mouse

Tested Applications

ELISA, WB, IF; Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:200

Background

Ubiquitin-editing enzyme that contains both ubiquitin ligase and deubiquitinase activities. Involved in immune and inflammatory responses signaled by cytokines, such as TNF-alpha and IL-1 beta, or pathogens via Toll-like receptors (TLRs) through terminating NF-kappa-B activity. Essential component of a ubiquitin-editing protein complex, comprising also RNF11, ITCH and TAX1BP1, that ensures the transient nature of inflammatory signaling pathways. In cooperation with TAX1BP1 promotes disassembly of E2-E3 ubiquitin protein ligase complexes in IL-1R and TNFR-1 pathways; affected are at least E3 ligases TRAF6, TRAF2 and BIRC2, and E2 ubiquitin-conjugating enzymes UBE2N and UBE2D3. In cooperation with TAX1BP1 promotes ubiquitination of UBE2N and proteasomal degradation of UBE2N and UBE2D3. Upon TNF stimulation, deubiquitinates \\\'Lys-63\\\'-polyubiquitin chains on RIPK1 and catalyzes the formation of \\\'Lys-48\\\'-polyubiquitin chains. This leads to RIPK1 proteasomal degradation and consequently termination of the TNF- or LPS-mediated activation of NF-kappa-B. Deubiquitinates TRAF6 probably acting on \\\'Lys-63\\\'-linked polyubiquitin. Upon T-cell receptor (TCR)-mediated T-cell activation, deubiquitinates \\\'Lys-63\\\'-polyubiquitin chains on MALT1 thereby mediating disassociation of the CBM (CARD11:BCL10:MALT1) and IKK complexes and preventing sustained IKK activation. Deubiquitinates NEMO/IKBKG; the function is facilitated by TNIP1 and leads to inhibition of NF-kappa-B activation. Upon stimulation by bacterial peptidoglycans, probably deubiquitinates RIPK2. Can also inhibit I-kappa-B-kinase (IKK) through a non-catalytic mechanism which involves polyubiquitin; polyubiquitin promotes association with IKBKG and prevents IKK MAP3K7-mediated phosphorylation. Targets TRAF2 for lysosomal degradation. In vitro able to deubiquitinate \\\'Lys-11\\\'-, \\\'Lys-48\\\'- and \\\'Lys-63\\\' polyubiquitin chains. Inhibitor of programmed cell death. Has a role in the function of the lymphoid system. Required for LPS-induced production of proinflammatory cytokines and IFN beta in LPS-tolerized macrophages.

Clonality

Polyclonal

Isotype

IgG

Purification Method

>95%, Protein G purified

Conjugate

Non-conjugated

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid

Stroage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Names

TNFAIP3

Research Areas

Epigenetics and Nuclear Signaling; Cancer; Immunology; Signal transduction